Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy
Authors:
- 8 July 2020
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 127 (6) , 495-504
Abstract
Since voriconazole plasma trough concentration (VPC) is related to its efficacy and adverse events, therapeutic drug monitoring (TDM) is recommended to perform. However, there is no report about the data of voriconazole TDM in critically ill patients in China. This retrospective study was performed to determine whether voriconazole TDM was associated with treatment response and/or voriconazole adverse events in critically ill patients, and to identify the potential risk factors associated with VPC. A total of 216 critically ill patients were included. Patients were divided into two groups: those underwent voriconazole TDM (TDM group, n = 125) or did not undergo TDM (non‐TDM group, n = 91). The clinical response and adverse events were recorded and compared. Furthermore, in TDM group, multivariate logistic regression analysis was performed to identify the possible risk factors resulting in the variability in initial VPC. The complete response in the TDM group was significantly higher than that in the non‐TDM group (P = .012). The incidence of adverse events strongly associated with voriconazole in the non‐TDM group was significantly higher than that in the TDM group (19.8% vs 9.6%; P = .033). The factors, including age (OR 0.934, 95% CI: 0.906‐0.964), male (OR 5.929, 95% CI: 1.524‐23.062), serum albumin level (OR 1.122, 95% CI: 1.020‐1.234), diarrhoea (OR 4.953, 95% CI: 1.495‐16.411) and non‐intravenous administration (OR 4.763, 95% CI: 1.576‐14.39), exerted the greatest effects on subtherapeutic VPC (VPC < 1.5 mg/L) in multivariate analysis. Intravenous administration (OR 7.657, 95% CI: 1.957‐29.968) was a significant predictor of supratherapeutic VPC (VPC > 4.0 mg/L). TDM can result in a favourable clinical efficacy and a lower incidence of adverse events strongly associated with voriconazole in critically ill patients. Subtherapeutic VPC was closely related to younger age, male, hyperalbuminaemia, diarrhoea and non‐intravenous administration, and intravenous administration was a significant predictor of supratherapeutic VPC.Keywords
This publication has 44 references indexed in Scilit:
- Fungal infections in the ICUCurrent Opinion in Critical Care, 2015
- Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infectionsInternational Journal of Antimicrobial Agents, 2014
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled TrialClinical Infectious Diseases, 2012
- Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypesInternational Journal of Antimicrobial Agents, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Invasive Aspergillosis in the Intensive Care UnitClinical Infectious Diseases, 2007
- Voriconazole Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2006
- Invasive candidiasis in the intensive care unitCritical Care Medicine, 2006
- Voriconazole in the treatment of invasive fungal infectionsIntensive and Critical Care Nursing, 2005
- The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplantsTransplant Infectious Disease, 2002